secwatch.observer — SEC 8-K summary
======================================

Issuer:     Ernexa Therapeutics Inc. (ERNA)
CIK:        0000748592
Form:       8-K
Filed at:   2023-08-10T23:59:59+00:00
Accession:  0001140361-23-039073
Event type: regulatory
Sentiment:  negative
Materiality: 0.75
Item codes: 3.01, 5.02
LLM model:  deepseek-v4-flash:cloud@v2

CEO resigns, then reappointed; board resignations trigger Nasdaq non-compliance
-------------------------------------------------------------------------------

- CEO Dr. Angel resigned Aug 4 citing board's exclusion from business dev; rescinded Aug 8, reappointed Aug 9.
- Directors Binder and Wagner resigned Aug 8; Board reduced to two members (Wexler, Fiore).
- Nasdaq notified non-compliance with independent director, audit & compensation committee rules.
- Company has 45 days to submit compliance plan; up to 180-day extension possible if plan accepted.
- Company actively searching for new directors to fill vacancies and regain compliance.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/748592/000114036123039073/0001140361-23-039073-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/748592/000114036123039073/brhc20057343_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-23-039073

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer